PremiumThe FlyPerspective announces first patient dosed in Phase 1/2a trial of 212PbVMT01 Perspective Therapeutics price target lowered to $10 from $21 at Truist Positive Outlook for Perspective Therapeutics Despite Wider Net Loss, Supported by Strong Cash Position and Upcoming Catalysts PremiumPre-EarningsCATX Earnings this Week: How Will it Perform? Promising Clinical Developments and Unique Mechanism Drive Buy Rating for Perspective Therapeutics Promising Developments and Strategic Trial Design Justify Buy Rating for Perspective Therapeutics PremiumThe FlyPerspective Therapeutics initiated with an Outperform at Scotiabank Promising Outlook for Perspective Therapeutics: Buy Rating Backed by Positive Trial Data and Market Positioning Perspective continues to pursue dose escalation of 212PbVMT-alpha-NET 
